JP2018501797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501797A5 JP2018501797A5 JP2017534611A JP2017534611A JP2018501797A5 JP 2018501797 A5 JP2018501797 A5 JP 2018501797A5 JP 2017534611 A JP2017534611 A JP 2017534611A JP 2017534611 A JP2017534611 A JP 2017534611A JP 2018501797 A5 JP2018501797 A5 JP 2018501797A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- output
- protein
- recombinant probiotic
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 claims 24
- 230000000529 probiotic effect Effects 0.000 claims 24
- 235000018291 probiotics Nutrition 0.000 claims 24
- 108090000623 proteins and genes Proteins 0.000 claims 21
- 102000004169 proteins and genes Human genes 0.000 claims 21
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241001302654 Escherichia coli Nissle 1917 Species 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 1
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 101150026571 nasD gene Proteins 0.000 claims 1
- 101150055219 nrfA gene Proteins 0.000 claims 1
- 101150114893 oxyR gene Proteins 0.000 claims 1
- 229960002181 saccharomyces boulardii Drugs 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 101150025268 yeaR gene Proteins 0.000 claims 1
- 101150066411 ytfE gene Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095415P | 2014-12-22 | 2014-12-22 | |
| US62/095,415 | 2014-12-22 | ||
| PCT/US2015/067435 WO2016106343A1 (en) | 2014-12-22 | 2015-12-22 | Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018501797A JP2018501797A (ja) | 2018-01-25 |
| JP2018501797A5 true JP2018501797A5 (https=) | 2019-02-07 |
Family
ID=55273522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534611A Pending JP2018501797A (ja) | 2014-12-22 | 2015-12-22 | 炎症性大腸疾患の診断、モニタリング、および処置のためのプロバイオティック生物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20170360850A1 (https=) |
| EP (1) | EP3237437A1 (https=) |
| JP (1) | JP2018501797A (https=) |
| AU (1) | AU2015369627A1 (https=) |
| CA (1) | CA2971876A1 (https=) |
| WO (1) | WO2016106343A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160206666A1 (en) | 2014-12-22 | 2016-07-21 | Synlogic, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier |
| US11685925B2 (en) | 2015-10-30 | 2023-06-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
| EP3622093A4 (en) * | 2017-05-12 | 2021-05-26 | Baylor College of Medicine | DEVELOPMENT OF MICROBIAL BIOSENSORS FOR INTESTINAL IGNITION |
| WO2019047166A1 (en) | 2017-09-08 | 2019-03-14 | New Portal Limited | NUCLEIC ACID SYSTEMS THAT ALLOW BACTERIA TO SPECIFICALLY TARGET SOLID TUMORS THROUGH GLUCOSE DEPENDENT VIABILITY |
| WO2019203802A1 (en) | 2018-04-17 | 2019-10-24 | Massachusetts Institute Of Technology | An ingestible system to monitor gastrointestinal health in situ |
| JP2022512639A (ja) * | 2018-10-09 | 2022-02-07 | セカンド ゲノム インコーポレイテッド | 上皮バリア機能障害の治療に有効なタンパク質を送達するためのラクトコッカス・ラクティス発現系 |
| US11926849B2 (en) | 2019-03-29 | 2024-03-12 | The General Hospital Corporation | Biosensors in human gut organoids |
| CA3142608A1 (en) | 2019-06-04 | 2020-12-10 | Cocoon Biotech Inc. | Silk-based products, formulations, and methods of use |
| WO2021048172A2 (en) | 2019-09-09 | 2021-03-18 | River Stone Biotech Aps | Delivery vehicle for in situ delivering of pharmaceutical agents |
| WO2022006748A1 (en) | 2020-07-07 | 2022-01-13 | New Portal Limited | Genetically engineered live bacteria and methods of constructing the same |
| CN112961872B (zh) * | 2021-02-25 | 2022-09-30 | 上海健康医学院 | 益生菌嵌合传感器及其构建方法和应用 |
| EP4508236A4 (en) * | 2022-04-13 | 2026-04-15 | Baylor College Medicine | Bacterial biosensors for the diagnosis and treatment of inflammation |
| WO2025233942A1 (en) * | 2024-05-07 | 2025-11-13 | Technion Research & Development Foundation Limited | Synthetic microbiome consortia and use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0501540D0 (en) * | 2005-01-25 | 2005-03-02 | Univ Leeds | Controlled production and delivery of biologically active agents by gut bacteria |
| CN105144204B (zh) * | 2012-12-13 | 2018-02-27 | 麻省理工学院 | 基于重组酶的逻辑与存储系统 |
-
2015
- 2015-12-22 AU AU2015369627A patent/AU2015369627A1/en not_active Abandoned
- 2015-12-22 CA CA2971876A patent/CA2971876A1/en not_active Abandoned
- 2015-12-22 US US15/535,831 patent/US20170360850A1/en not_active Abandoned
- 2015-12-22 WO PCT/US2015/067435 patent/WO2016106343A1/en not_active Ceased
- 2015-12-22 JP JP2017534611A patent/JP2018501797A/ja active Pending
- 2015-12-22 EP EP15831026.8A patent/EP3237437A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018501797A5 (https=) | ||
| Budisan et al. | Links between infections, lung cancer, and the immune system | |
| Conti et al. | IL-17 receptor signaling in oral epithelial cells is critical for protection against oropharyngeal candidiasis | |
| Mays et al. | Synthetic biology in probiotic lactic acid bacteria: At the frontier of living therapeutics | |
| Linares et al. | Genome sequences of Lactococcus lactis MG1363 (revised) and NZ9000 and comparative physiological studies | |
| JP2016520290A5 (https=) | ||
| JP2014510520A5 (https=) | ||
| Waisman | To be 17 again—Anti–interleukin-17 treatment for psoriasis | |
| Aebisher et al. | Key interleukins in inflammatory bowel disease—a review of recent studies | |
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| FI3461491T3 (fi) | Tehostettu adoptiivinen soluterapia | |
| Reikvam et al. | The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation | |
| JP2016525516A5 (https=) | ||
| Liu et al. | Complete genome sequence of Xanthomonas campestris pv. campestris strain 17 from Taiwan | |
| JP2021526854A (ja) | 鉄代謝および腸内マイクロバイオームの健康の改善のための組成物および方法 | |
| Mansoor et al. | Expression of IFN-Gamma is significantly reduced during severity of covid-19 infection in hospitalized patients | |
| Botros et al. | Study of the role of IL-17F gene polymorphism in the development of immune thrombocytopenia among the Egyptian children | |
| Li et al. | The pivotal role of cytokines in liver disease pathogenesis and therapeutic potential | |
| JP2025503989A (ja) | 治療用サイトカイン及び方法 | |
| Barathiraja et al. | Expression and purification of biologically active bovine interferon λ3 (IL28B) in Pichia pastoris | |
| Taheri et al. | Lack of association between interleukin-18-607 C/A gene polymorphism and pulmonary tuberculosis in Zahedan, Southeast Iran | |
| JP2018512844A5 (https=) | ||
| Timmermans et al. | Using the inbred mouse strain SPRET/EiJ to provide novel insights in inflammation and infection research | |
| Heidari et al. | Genome-wide association studies: type 2 diabetes | |
| Wang et al. | Construction of probiotic Escherichia coli Nissle 1917 as a next-generation expression platform and its application in therapeutic protein production |